Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There has been interest in the clinical potential of bone turnover markers (BTMs) as tools both for assessing fracture risk and for monitoring treatment. However, the practical use of BTMs has been limited by their biological variability and difficulties in the interpretation of results. We investigated the current situation of application of BTMs by clinicians in Korea for the management of osteoporosis through a survey asking the patterns of BTMs prescription in clinical practice. Methods: The survey was conducted online using the “google survey” by the BTM committee authorized by the Korean Society for Bone and Mineral Research. Results: Total 108 clinicians responded the survey. Most of the respondents prescribed BTMs (80.6%) when they prescribed anti-osteoporotic medications (AOMs). The most frequently prescribed bone resorption and formation markers were serum C-terminal telopeptide of type I collagen (90.7%) and osteocalcin (65.1%), respectively. BTMs were mostly prescribed before starting AOMs (90.8%) and used for the purpose of evaluating treatment response (74.4%). Treatment response and compliance to AOMs were evaluated according to the change of absolute value of BTMs (55.1%). The respondents complained difficulties in the interpretation of BTMs (33.3%), the choice of proper BTMs (17.2%), and the proper sample preparation and handling (13.8%). Conclusions: In Korea, most of clinicians recognized the benefit of BTMs in the management of osteoporosis. However, there are limitations in the broad use of these markers in clinical practice. Therefore, a clear recommendation for BTM in Korea enhances their use in clinical practice.
Abstract
Background: There has been interest in the clinical potential of bone turnover markers (BTMs) as tools both for assessing fracture risk and for monitoring treatment. However, the practical use of BTMs has been limited by their biological variability and difficulties in the interpretation of results. We investigated the current situation of application of BTMs by clinicians in Korea for the management of osteoporosis through a survey asking the patterns of BTMs prescription in clinical practice. Methods: The survey was conducted online using the “google survey” by the BTM committee authorized by the Korean Society for Bone and Mineral Research. Results: Total 108 clinicians responded the survey. Most of the respondents prescribed BTMs (80.6%) when they prescribed anti-osteoporotic medications (AOMs). The most frequently prescribed bone resorption and formation markers were serum C-terminal telopeptide of type I collagen (90.7%) and osteocalcin (65.1%), respectively. BTMs were mostly prescribed before starting AOMs (90.8%) and used for the purpose of evaluating treatment response (74.4%). Treatment response and compliance to AOMs were evaluated according to the change of absolute value of BTMs (55.1%). The respondents complained difficulties in the interpretation of BTMs (33.3%), the choice of proper BTMs (17.2%), and the proper sample preparation and handling (13.8%). Conclusions: In Korea, most of clinicians recognized the benefit of BTMs in the management of osteoporosis. However, there are limitations in the broad use of these markers in clinical practice. Therefore, a clear recommendation for BTM in Korea enhances their use in clinical practice.
참고문헌 (26)
- Burge R, "Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025", J Bone Miner Res, 22, pp.465~475 (2007)
- Kang HY, "Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data", BMC Public Health, 10, pp.230~ (2010)
- Kanis JA, "A reference standard for the description of osteoporosis", Bone, 42, pp.467~475 (2008)
- Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
- Garnero P, "Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study", J Bone Miner Res, 11, pp.1531~1538 (1996)
- Hans D, "Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study", J Bone Miner Res, 26, pp.2762~2769 (2011)
- Jain RK, "Dual-energy X-ray absorptiometry", J Clin Densitom, 20, pp.291~303 (2017)
- Brown JP, "Bone turnover markers in the management of postmenopausal osteoporosis", Clin Biochem, 42, pp.929~942 (2009)
- Szulc P, "Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis", Osteoporos Int, 19, pp.1683~1704 (2008)
- Vasikaran SD, "Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis", Crit Rev Clin Lab Sci, 45, pp.221~258 (2008)
- Bergmann P, "Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club", Int J Clin Pract, 63, pp.19~26 (2009)
- Hannon R, "Preanalytical variability of biochemical markers of bone turnover", Osteoporos Int, 11(Suppl 6), pp.S30~S44 (2000)
- Seibel MJ, "Interlaboratory variation of biochemical markers of bone turnover", Clin Chem, 47, pp.1443~1450 (2001)
- Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)
- 박소영, "Clinical Application of Bone Turnover Markers in Osteoporosis in Korea", 대한골대사학회지, 26(1), pp.19~24 (2019), 대한골대사학회
- Nishizawa Y, "Executive summary of the Japan osteoporosis society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 Edition)", Clin Chim Acta, 498, pp.101~107 (2019)
- Szulc P, "Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability", Osteoporos Int, 28, pp.2541~2556 (2017)
- Bhattoa HP, "Laboratory aspects and clinical utility of bone turnover markers", Ejifcc, 29, pp.117~128 (2018)
- Bauer DC, "Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial", J Bone Miner Res, 21, pp.292~299 (2006)
- Eastell R, "Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate", J Bone Miner Res, 18, pp.1051~1056 (2003)
- Clowes JA, "The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial", J Clin Endocrinol Metab, 89, pp.1117~1123 (2004)
- Delmas PD, "Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis", J Clin Endocrinol Metab, 92, pp.1296~1304 (2007)
- Christiansen C, "Prediction of rapid bone loss in postmenopausal women", Lancet, 1, pp.1105~1108 (1987)
- Garnero P, "Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis", J Bone Miner Res, 11, pp.337~349 (1996)
- Bauer D, "National bone health alliance bone turnover marker project: Current practices and the need for US harmonization, standardization, and common reference ranges", Osteoporos Int, 23, pp.2425~2433 (2012)
- Weiss TW, "Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study", Osteoporos Int, 18, pp.1473~1480 (2007)